Source: FDA label
| Molecular formula | C184H282N50O60S |
|---|---|
| Molecular weight | 4187 g/mol |
| Registered trials | 406 |
| PubChem CID | 45588096 |
| Drug class | GLP-1 Receptor Agonist [EPC] |
| Brand names | Byetta |
Mechanism of Action
12.1 Mechanism of Action Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. BYETTA is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. The amino acid sequence of exenatide partially overlaps that of human GLP-1. E
What Exenatide Is
Exenatide is a peptide compound with the molecular formula C184H282N50O60S, identifiable by PubChem CID 45588096. Research use of exenatide as covered here refers to its status outside any approved labeling context, and this summary does not describe an approved drug label. Products containing this compound under the brand name Byetta have been formulated as a GLP-1 receptor agonist in other regulatory contexts, but the material discussed here is presented strictly as a research compound.
Trial Footprint
A total of 406 trials referencing exenatide are registered. Sampled records include a completed Phase 4 study comparing exenatide to Lantus insulin for vascular function in type 2 diabetes, a completed Phase 3 study comparing exenatide (AC2993) with insulin glargine alongside sulfonylurea and metformin therapy, and a recruiting Phase 2 study examining GLP-1 receptor agonism in multiple sclerosis. These entries reflect the range of conditions and populations studied, not confirmed outcomes.
Reported Reactions
Reported reactions associated with exenatide in adverse event reports center on glucose and metabolic measures alongside gastrointestinal symptoms: blood glucose increased (15,473 reports), weight decreased (12,125), and nausea (12,043). Additional frequently reported terms include decreased appetite, blood glucose decreased, vomiting, diarrhoea, and dizziness. These figures represent counts of submitted reports, not confirmed incidence rates or established causation.
FAQ
Is exenatide FDA approved?
This summary addresses exenatide strictly as a research compound and does not describe an approved use. Regulatory status can vary by product and jurisdiction, so consult official regulatory sources for current status.
What is exenatide's chemical identity?
Exenatide is a peptide with the molecular formula C184H282N50O60S. It is catalogued under PubChem CID 45588096.
How many clinical trials have studied exenatide?
There are 406 registered trials referencing exenatide. These span a range of study phases and conditions, including completed and actively recruiting studies.
What side effects have been reported with exenatide?
Adverse event reports most commonly mention changes in blood glucose, decreased weight, and nausea, along with decreased appetite, vomiting, diarrhoea, and dizziness. These are counts of submitted reports and do not establish that exenatide caused the reactions.
What conditions has exenatide been studied for?
Sampled trials include research in type 2 diabetes contexts as well as a study exploring GLP-1 receptor agonism in multiple sclerosis. This reflects the scope of registered research rather than any established benefit.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov FDA FAERS
Updated 2026-08-22